Ketone Ester Effects on Biomarkers of Brain Metabolism and Cognitive Performance in Cognitively Intact Adults ≥ 55 Years Old. A Study Protocol for a Double-Blinded Randomized Controlled Clinical Trial

被引:5
|
作者
Avgerinos, K., I [1 ]
Mullins, R. J. [1 ]
Egan, J. M. [1 ]
Kapogiannis, D. [1 ]
机构
[1] NIA, NIH, Lab Clin Invest, 251 Bayview Blvd,8C228, Baltimore, MD 21224 USA
来源
关键词
Ketosis; ketone ester; metabolic syndrome; Alzheimer's disease; magnetic resonance spectroscopy; cognition; extracellular vesicles; ALZHEIMERS-DISEASE; MOUSE MODEL; GLUCOSE-METABOLISM; SPECTROSCOPY; EXOSOMES; MILD; ABNORMALITIES; PROTEINS; CHILDREN; EFFICACY;
D O I
10.14283/jpad.2022.3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Ketone bodies have been proposed as an "energy rescue" for the Alzheimer's disease (AD) brain, which underutilizes glucose. Prior research has shown that oral ketone monoester (KME) safely induces robust ketosis in humans and has demonstrated cognitive-enhancing and pathology-reducing properties in animal models of AD. However, human evidence that KME may enhance brain ketone metabolism, improve cognitive performance and engage AD pathogenic cascades is scarce. Objectives To investigate the effects of ketone monoester (KME) on brain metabolism, cognitive performance and AD pathogenic cascades in cognitively normal older adults with metabolic syndrome and therefore at higher risk for AD. DESIGN: Double-blinded randomized placebo-controlled clinical trial. Setting Clinical Unit of the National Institute on Aging, Baltimore, US. Participants Fifty cognitively intact adults >= 55 years old, with metabolic syndrome. Intervention Drinks containing 25 g of KME or isocaloric placebo consumed three times daily for 28 days. Outcomes Primary: concentration of beta-hydroxybutyrate (BHB) in precuneus measured with Magnetic Resonance Spectroscopy (MRS). Exploratory: plasma and urine BHB, multiple brain and muscle metabolites detected with MRS, cognition assessed with the PACC and NIH toolbox, biomarkers of AD and metabolic mediators in plasma extracellular vesicles, and stool microbiome. Discussion This is the first study to investigate the AD-biomarker and cognitive effects of KME in humans. Ketone monoester is safe, tolerable, induces robust ketosis, and animal studies indicate that it can modify AD pathology. By conducting a study of KME in a population at risk for AD, we hope to bridge the existing gap between pre-clinical evidence and the potential for brain-metabolic, pro-cognitive, and anti-Alzheimer's effects in humans.
引用
收藏
页码:54 / 66
页数:13
相关论文
共 50 条
  • [31] Effectiveness and safety of Bushen Huoxue granules in treatment of premature ovarian insufficiency: study protocol for a randomized, double-blinded, placebo-controlled, and multicenter clinical trial
    Cao, Ying
    Wang, Peijuan
    Lu, Yan
    Chen, Yue
    Chen, Si
    Zhao, Weibo
    [J]. TRIALS, 2021, 22 (01)
  • [32] GLP-1 analogue liraglutide prevents decline of brain glucose metabolism in Alzheimer's Disease: Randomized, placebo-controlled double-blinded clinical trial
    Gejl, M.
    Egejord, L.
    Moller, A.
    Hansen, S. B.
    Vang, K.
    Rodell, A.
    Braendgaard, H.
    Gottrup, H.
    Schacht, A.
    Moller, N.
    Brock, B.
    Rungby, J.
    Gjedde, A.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S132 - S133
  • [33] Correction: Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline (SmartAge)—study protocol for a randomized controlled trial
    Miranka Wirth
    Claudia Schwarz
    Gloria Benson
    Nora Horn
    Ralph Buchert
    Catharina Lange
    Theresa Köbe
    Stefan Hetzer
    Marta Maglione
    Eva Michael
    Stefanie Märschenz
    Knut Mai
    Ute Kopp
    Dietmar Schmitz
    Ulrike Grittner
    Stephan J. Sigrist
    Slaven Stekovic
    Frank Madeo
    Agnes Flöel
    [J]. Alzheimer's Research & Therapy, 14
  • [34] Effects of Neuromuscular Electrical Stimulation on Plantarflexors Spasticity, Gait Performance, and Self-Reported Health Outcomes in People With Chronic Stroke: A Study Protocol for a Double-Blinded Randomized Clinical Trial
    Almutairi, Sattam M.
    Khalil, Mohamed E.
    Almutairi, Nadiah
    Alenazi, Aqeel M.
    [J]. FRONTIERS IN NEUROLOGY, 2021, 12
  • [35] Atorvastatin for reduction of 28-day mortality in hospitalized COVID-19 patients: study protocol for a randomized, double-blinded, placebo-controlled, clinical trial
    Emara, Moataz Maher
    Elsawy, Neamat Hamdy
    Abdelaaty, Kholoud M.
    Elhamaky, Amal Salah
    Eltahan, Naglaa Hamdi
    [J]. TRIALS, 2022, 23 (01)
  • [36] Caffeine-Containing, Adaptogenic-Rich Drink Modulates the Effects of Caffeine on Mental Performance and Cognitive Parameters: A Double-Blinded, Placebo-Controlled, Randomized Trial
    Boolani, Ali
    Fuller, Daniel T.
    Mondal, Sumona
    Wilkinson, Tyler
    Darie, Costel C.
    Gumpricht, Eric
    [J]. NUTRIENTS, 2020, 12 (07) : 1 - 26
  • [37] Functional outcome of total knee replacement: a study protocol for a prospective, double-blinded, parallel-group randomized, clinical controlled trial of novel, personalized and conventional implants
    Irmola, T.
    Kangas, J.
    Eskelinen, A.
    Niemelainen, M.
    Huhtala, H.
    Mattila, V. M.
    Moilanen, T.
    [J]. BMC MUSCULOSKELETAL DISORDERS, 2019, 20 (01)
  • [38] Atorvastatin for reduction of 28-day mortality in hospitalized COVID-19 patients: study protocol for a randomized, double-blinded, placebo-controlled, clinical trial
    Moataz Maher Emara
    Neamat Hamdy Elsawy
    Kholoud M. Abdelaaty
    Amal Salah Elhamaky
    Naglaa Hamdi Eltahan
    [J]. Trials, 23
  • [39] The efficacy and safety of sulforaphane as an adjuvant in the treatment of bipolar depressive disorder Study protocol for a randomized, double-blinded, placebo-controlled, parallel-group clinical trial
    Wu, Congchong
    Chen, Xingyang
    Lai, Jianbo
    Xu, Yi
    Hu, Shaohua
    [J]. MEDICINE, 2020, 99 (26) : E20981
  • [40] Functional outcome of total knee replacement: a study protocol for a prospective, double-blinded, parallel-group randomized, clinical controlled trial of novel, personalized and conventional implants
    T. Irmola
    J. Kangas
    A. Eskelinen
    M. Niemeläinen
    H. Huhtala
    V. M. Mattila
    T. Moilanen
    [J]. BMC Musculoskeletal Disorders, 20